1. Home
  2. XAIR vs INBS Comparison

XAIR vs INBS Comparison

Compare XAIR & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.37

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.27

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
INBS
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.7M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
XAIR
INBS
Price
$0.37
$2.27
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
204.8K
79.5K
Earning Date
06-16-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
62.09
68.65
EPS
N/A
N/A
Revenue
$3,705,000.00
$1,980,484.00
Revenue This Year
$122.00
$778.48
Revenue Next Year
$58.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
219.67
N/A
52 Week Low
$0.15
$0.54
52 Week High
$3.78
$24.90

Technical Indicators

Market Signals
Indicator
XAIR
INBS
Relative Strength Index (RSI) 35.55 36.84
Support Level N/A $0.59
Resistance Level $0.59 $3.16
Average True Range (ATR) 0.04 0.15
MACD -0.00 -0.01
Stochastic Oscillator 17.09 2.59

Price Performance

Historical Comparison
XAIR
INBS

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

Share on Social Networks: